Ep192: Kate Haviland on Following the Science to Precision Immunology episode artwork

EPISODE · Jan 8, 2026 · 1H 26M

Ep192: Kate Haviland on Following the Science to Precision Immunology

from The Long Run with Luke Timmerman · host Timmerman Report

Kate Haviland, former CEO of Blueprint Medicines, on how the company transitioned to a precision immunology company and was acquired by Sanofi for $9.5 billion.

Kate Haviland, former CEO of Blueprint Medicines, on how the company transitioned to a precision immunology company and was acquired by Sanofi for $9.5 billion.

NOW PLAYING

Ep192: Kate Haviland on Following the Science to Precision Immunology

0:00 1:26:06

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of The Long Run with Luke Timmerman?

This episode is 1 hour and 26 minutes long.

When was this The Long Run with Luke Timmerman episode published?

This episode was published on January 8, 2026.

What is this episode about?

Kate Haviland, former CEO of Blueprint Medicines, on how the company transitioned to a precision immunology company and was acquired by Sanofi for $9.5 billion.

Can I download this The Long Run with Luke Timmerman episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!